| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 24032 |
| Drug | Amivantamab |
| Brand | Rybrevant® |
| Indication | Amivantamab (Rybrevant®) in combination with carboplatin and pemetrexed is indicated for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion |
| Assessment Process | |
| Rapid review commissioned | 31/07/2024 |
| Rapid review completed | 30/09/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of amivantamab for this indication compared with the current standard of care. |
| Full HTA commissioned by the HSE | 30/10/2024 |
| Pre-submission consultation with Applicant | 03/12/2024 |
| Full submission received from Applicant | 25/04/2025 |
| Preliminary review sent to Applicant | 14/10/2025 |
| NCPE assessment re-commenced | 27/11/2025 |
| Factual accuracy sent to Applicant | 12/02/2026 |
| NCPE assessment re-commenced | 20/02/2026 |
| NCPE assessment completed | 10/03/2026 |
| NCPE assessment outcome | The NCPE recommends that amivantamab, in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced NSCLC with activating epidermal EGFR exon20ins mutations, should not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.